Synaptic oligomeric tau in Alzheimer's disease - A potential culprit in the spread of tau pathology through the brain.
Alzheimer
synapse
tau
Journal
Neuron
ISSN: 1097-4199
Titre abrégé: Neuron
Pays: United States
ID NLM: 8809320
Informations de publication
Date de publication:
19 07 2023
19 07 2023
Historique:
received:
12
08
2022
revised:
15
03
2023
accepted:
17
04
2023
medline:
23
10
2023
pubmed:
17
5
2023
entrez:
16
5
2023
Statut:
ppublish
Résumé
In Alzheimer's disease, fibrillar tau pathology accumulates and spreads through the brain and synapses are lost. Evidence from mouse models indicates that tau spreads trans-synaptically from pre- to postsynapses and that oligomeric tau is synaptotoxic, but data on synaptic tau in human brain are scarce. Here we used sub-diffraction-limit microscopy to study synaptic tau accumulation in postmortem temporal and occipital cortices of human Alzheimer's and control donors. Oligomeric tau is present in pre- and postsynaptic terminals, even in areas without abundant fibrillar tau deposition. Furthermore, there is a higher proportion of oligomeric tau compared with phosphorylated or misfolded tau found at synaptic terminals. These data suggest that accumulation of oligomeric tau in synapses is an early event in pathogenesis and that tau pathology may progress through the brain via trans-synaptic spread in human disease. Thus, specifically reducing oligomeric tau at synapses may be a promising therapeutic strategy for Alzheimer's disease.
Identifiants
pubmed: 37192625
pii: S0896-6273(23)00305-7
doi: 10.1016/j.neuron.2023.04.020
pii:
doi:
Substances chimiques
Amyloid beta-Peptides
0
tau Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2170-2183.e6Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests T.S.-J. is on the Scientific Advisory Board of Cognition Therapeutics and has received honoraria for talks for industry collaborators. They did not have any involvement in or influence over the current paper. T.S.-J. is also a member of the Neuron Editorial Advisory Board.